<SEC-DOCUMENT>0001209191-18-002576.txt : 20180105
<SEC-HEADER>0001209191-18-002576.hdr.sgml : 20180105
<ACCEPTANCE-DATETIME>20180105194710
ACCESSION NUMBER:		0001209191-18-002576
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20180103
FILED AS OF DATE:		20180105
DATE AS OF CHANGE:		20180105

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Braunstein Scott
		CENTRAL INDEX KEY:			0001643875

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35060
		FILM NUMBER:		18514620

	MAIL ADDRESS:	
		STREET 1:		C/O ESPERION THERAPEUTICS, INC.
		STREET 2:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pacira Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510619477
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054
		BUSINESS PHONE:		973-254-3560

	MAIL ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2018-01-03</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001396814</issuerCik>
        <issuerName>Pacira Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>PCRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001643875</rptOwnerCik>
            <rptOwnerName>Braunstein Scott</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PACIRA PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>5 SYLVAN WAY, SUITE 300</rptOwnerStreet2>
            <rptOwnerCity>PARSIPPANY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07054</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Operating Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>46.35</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2018-01-03</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>60000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2028-01-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>60000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>60000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Kristen Williams, Attorney-in-Fact</signatureName>
        <signatureDate>2018-01-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
